SNN Overview

Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system.

Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is35.75 USD with a low forecast of 34.00 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Smith & Nephew PLC revenue for the last quarter amounts to NaN USD, decreased

Smith & Nephew PLC. EPS for the last quarter amounts to USD, decreased

Smith & Nephew PLC (SNN) has 16988 emplpoyees as of May 31 2026.

Today SNN has the market capitalization of 12.62B USD.